# Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

> **NCT07100600** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 224 (estimated)

## Conditions studied

- HER2-positive Advanced Breast Cancer
- Brain Metastases
- Radiotherapy

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **RADIATION:** FSRT or WBRT

## Key facts

- **NCT ID:** NCT07100600
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2030-07-30
- **Final completion:** 2032-12-30
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100600, "Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07100600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*